KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Average (2016 - 2025)

Historic Equity Average for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to $596.7 million.

  • Xenon Pharmaceuticals' Equity Average fell 2730.85% to $596.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $596.7 million, marking a year-over-year decrease of 2730.85%. This contributed to the annual value of $841.4 million for FY2024, which is 202.53% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Equity Average of $596.7 million as of Q3 2025, which was down 2730.85% from $669.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Equity Average registered a high of $907.8 million during Q1 2024, and its lowest value of $223.8 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $669.0 million (2025), whereas its average is $632.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 20417.97% in 2022, then tumbled by 2730.85% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Equity Average (Quarter) stood at $399.5 million in 2021, then soared by 84.56% to $737.3 million in 2022, then grew by 6.1% to $782.3 million in 2023, then fell by 0.75% to $776.4 million in 2024, then fell by 23.14% to $596.7 million in 2025.
  • Its last three reported values are $596.7 million in Q3 2025, $669.0 million for Q2 2025, and $729.4 million during Q1 2025.